Comparison of surgery rates in biologic-naive patients with Crohn's disease treated with vedolizumab or ustekinumab: findings from SOJOURN.

ABSTRACT:

Background

Crohn's disease (CD) is a chronic inflammatory bowel disease characterized by relapsing and remitting inflammation that leads to progressive bowel damage. Despite advances in medical treatment for CD, many patients require surgical intervention. Most studies of surgery rates are from patients treated with anti-tumor necrosis factor alpha (anti-TNFα) treatments, with comparatively little data on the surgery rates of patients treated with vedolizumab and ustekinumab. SOJOURN aimed to estimate the hazard rate and incidence of the first CD-related surgery following initiation of treatment with vedolizumab or ustekinumab in biologic-naïve patients with CD.

Methods

SOJOURN was a retrospective, observational cohort study examining administrative claims data from the Optu

SUBMITTER: Vu M 

PROVIDER: S-EPMC10039499 | biostudies-literature | 2023 Mar

REPOSITORIES: biostudies-literature